<Suppliers Price>

BMS-779788

Names

[ CAS No. ]:
918348-67-1

[ Name ]:
BMS-779788

[Synonym ]:
1H-Imidazole-4-methanol, 2-[1-(2-chlorophenyl)-1-methylethyl]-α,α-dimethyl-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-
2-{2-[2-(2-Chlorophenyl)propan-2-Yl]-1-[3'-(Methylsulfonyl)biphenyl-4-Yl]-1h-Imidazol-4-Yl}propan-2-Ol
2-{2-[2-(2-Chlorophenyl)-2-propanyl]-1-[3'-(methylsulfonyl)-4-biphenylyl]-1H-imidazol-4-yl}-2-propanol

Biological Activity

[Description]:

BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> LXR
Research Areas >> Metabolic Disease

[Target]

IC50: 68 nM (LXRα); 14 nM (LXRβ)[1]


[In Vitro]

The LXR selective partial agonist BMS-779788 is identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50=1.2 μM, 55% efficacy)[2].

[In Vivo]

BMS-779788 induces LXR target genes in blood in vivo with an EC50=610 nM, a value similar to its in vitro blood gene induction potency. BMS-779788 is 29- and 12-fold less potent than the full agonist T0901317 in elevating plasma triglyceride and LDL cholesterol, respectively, with similar results for plasma cholesteryl ester transfer protein and apolipoprotein B[1]. In mice BMS-779788 displays peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist[2].

[Animal admin]

Monkeys: Male cynomolgus monkeys are used in the study. For a single-dose pharmacokinetic (PK)-pharmacodynamic (PD) study, 2 animals each are treated either with vehicle [0.5% carboxymethyl cellulose and 2% Tween 80 in purified water) or 1 mg/kg BMS-779788. For the 7 day PD study, 18 animals are randomized into 6 treatment groups (N=3/group; 3-6 kg) and received the following treatments at 7 AM daily for 7 days by oral gavage: vehicle, 10 mg/kg per day T0901317 and 0.3, 1, 3, or 10 mg/kg per day BMS-779788[1].

[References]

[1]. Kirchgessner TG, et al. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates. J Pharmacol Exp Ther. 2015 Feb;352(2):305-14.

[2]. Kick E, et al. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ. Bioorg Med Chem Lett. 2015 Jan 15;25(2):372-7.


[Related Small Molecules]

T0901317 | GW3965 HCl | WAY 252623 | SR 9243 | (20S)-Protopanaxatriol | 27-Hydroxycholesterol | GSK 2033 | AZ876 | SR 9238 | 24-Hydroxycholesterol | BMS-852927 | Nagilactone B | RGX-104 | Rovazolac

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
738.7±70.0 °C at 760 mmHg

[ Molecular Formula ]:
C28H29ClN2O3S

[ Molecular Weight ]:
509.060

[ Flash Point ]:
400.6±35.7 °C

[ Exact Mass ]:
508.158752

[ LogP ]:
4.85

[ Appearance of Characters ]:
light yellow solid

[ Vapour Pressure ]:
0.0±2.6 mmHg at 25°C

[ Index of Refraction ]:
1.605

[ Storage condition ]:
-20℃


Related Compounds